Neurocrine Biosciences (NBIX) EBITDA Margin (2010 - 2026)

Neurocrine Biosciences' EBITDA Margin history runs 16 years deep, the most recent figure standing at 23.74% for Q1 2026.

• Quarterly EBITDA Margin rose 1962.0% year-over-year to 23.74% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 25.43% (up 492.0% YoY) and the FY2025 annual result came in at 21.64%, down 258.0% from the prior year.
• EBITDA Margin was 23.74% for Q1 2026 at Neurocrine Biosciences, down from 26.18% in the prior quarter.
• Across five years, EBITDA Margin topped out at 273.5% in Q2 2022 and bottomed at 27.16% in Q1 2023.
• A 5-year average of 33.54% and a median of 23.74% in 2026 frame the typical range for EBITDA Margin.
• Annual changes were most pronounced in 2022 — EBITDA Margin jumped 25176 bps — and 2023, when it sank 25724 bps.
• Neurocrine Biosciences' EBITDA Margin stood at 25.1% in 2022, then increased by 16 bps to 29.17% in 2023, then dropped by 22 bps to 22.62% in 2024, then increased by 16 bps to 26.18% in 2025, then retreated by 9 bps to 23.74% in 2026.
• Business Quant data shows NBIX's EBITDA Margin at 23.74% in Q1 2026, 26.18% in Q4 2025, and 30.07% in Q3 2025.